TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $110
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $95 to $110.
TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $95 to $110.